REACH
Creo Medical Group plc
("Creo" or the "Company")
Creo opens Singapore regional hub
Commercial hub further strengthens Creo's footprint across Asia-Pacific region
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has officially opened its regional hub in Singapore, with the first-class facility providing a multi-functional centre for the commercial roll-out of Creo's products across the Asia-Pacific ("APAC") region.
The facility will provide a base for Creo's staff working across the region and includes a training centre, demonstration room, service centre and conference room.
The regional commercial hub also forms a key part of Creo's international strategy - providing a direct sales and marketing presence across APAC and will be central to the management of Creo's distribution partners in the APAC region. During the COVID-19 pandemic Creo has carefully selected and engaged with a number of distribution partners in the region including in South Korea, Hong Kong, Vietnam, Thailand, Malaysia, Indonesia, India, Sri Lanka and Australia. The hub will support these partners as they start to satisfy the backlog of demand in their markets as they emerge from the COVID-19 pandemic.
In addition, this carefully designed hub aims to accelerate ongoing technology and product development, with local innovation centres and universities already expressing interest in collaborating and partnering. The site also allows the Company to better target and engage with potential users across the region and more broadly showcase Creo's core technology and products to new markets.
A number of prominent KOLs were invited to attend the opening and meet the Creo team to discuss the benefits of Creo's innovative range of advanced energy devices. One such KOL, Clinical Assistant Professor Damien Tan, Director, Endoscopy Centre, Singapore General Hospital, Singapore, said "Creo's opening brings the latest cutting-edge technology in endoscopy to Singapore and the region. We are proud and excited to be able to work with this new and exciting technology."
Craig Gulliford, Chief Executive Officer of Creo, said: "It's fantastic to see this regional hub officially open - it's a first-rate facility which allows Creo to build on the important groundwork already done as we step up and roll out our products to new and exciting audiences and markets.
"The demand is clear from the engagement we've already had, and this commercial hub is a key cog in turning that demand into users and, ultimately, better outcomes for patients across APAC, whilst helping to deliver on our 'Build, Buy and Partner' strategy."
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Enquiries:
| Creo Medical Group plc | |
| Richard Rees (CFO) | +44 (0)1291 606 005 |
|
|
|
| Cenkos Securities plc | +44 (0)20 7397 8900 |
| Stephen Keys / Camilla Hume (NOMAD) |
|
| Michael Johnson / Russell Kerr (Sales) |
|
|
|
|
| Numis Securities Limited (Joint Broker) Freddie Barnfield / James Black / Duncan Monteith | +44 (0)20 7260 1000 |
|
|
|
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
| Paul McManus / Sam Allen / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
